Ovarian Cancer Misdiagnosis Claims in Ireland

An ovarian cancer misdiagnosis claim in Ireland is a clinical negligence action where a GP, radiologist, pathologist, or gynaecologist failed to investigate, refer, or diagnose the cancer to the standard required by the Dunne principles, and that failure caused harm. The standard is set in Dunne v National Maternity Hospital [1989] IR 91^[1]. The time limit is two years less one day from your date of knowledge under the Statute of Limitations (Amendment) Act 1991^[4]. The claim is exempt from the Injuries Resolution Board, formerly the Personal Injuries Assessment Board, under section 3(d) of the PIAB Act 2003^[5], and proceeds directly to the High Court on the Clinical Negligence List under Practice Direction HC131^[9].

On this page

• What counts as ovarian cancer misdiagnosis under Irish law?
• The Irish Ovarian Diagnostic Gate
• When does ovarian cancer get confused with IBS, a cyst, menopause, or a UTI?
• The Ovarian Histology Breach Matrix
• When is failing to act on BRCA or Lynch family history negligent?
• How is causation evidence built in Irish ovarian cancer claims?
• Why is the Irish ovarian pathway different from the UK pathway?
• What is the time limit for an ovarian cancer claim in Ireland?
• How much compensation can you claim?
• Who pays an ovarian cancer misdiagnosis claim in Ireland?
• How does the claim process actually work?
• Can you claim after a loved one has died?
• What are the common defences?
• What mistakes weaken or end a claim?
• Plain-English glossary
• Frequently asked questions
• References

Quick answers

Do I have a claim? You have a claim if a GP, radiologist, or specialist failed to investigate, refer, or diagnose to the Dunne standard and that failure caused harm.

How long do I have? Two years less one day from your date of knowledge under sections 2 and 3 of the Statute of Limitations (Amendment) Act 1991.

Do I go through the IRB? No. Medical negligence is exempt under section 3(d) of the PIAB Act 2003 and proceeds directly to the High Court.

What does it cost? Most Irish clinical negligence work runs on a deferred-fee basis under a Section 150 notice. A solicitor cannot calculate fees as a percentage of any award.

What's new for 2026

• Clinical Negligence List active. Practice Direction HC131^[9] took effect on 28 April 2025 and HC132^[10] created the Clinical Negligence List. Parties seeking a trial date must give an undertaking to offer mediation.
• Patient Safety Act commenced. The Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023^[8] was commenced on 26 September 2024^[16], introducing mandatory open disclosure of notifiable incidents and the cancer screening review right. The only part not yet commenced is section 68, which inserts a new section into the Health Act 2007 for HIQA reviews of certain nursing home incidents. The cancer screening review right under the Act applies to BreastCheck, CervicalCheck, and BowelScreen, so it does not directly cover ovarian cancer because there is no Irish ovarian screening programme.
• Personal Injuries Guidelines unchanged. The Judicial Council voted to approve a 16.7% uplift on 31 January 2025 and submitted it to the Minister for Justice in February 2025. The Government decided in July 2025 not to advance the amendments to the Oireachtas, so the original 2021 brackets remain applicable in 2026^[11].
• NCRI 2024 figures published. Around 370 new ovarian cancer cases per year in Ireland, with roughly 70% diagnosed at advanced stage. Ovarian cancer is the 5th leading cause of cancer death in women, according to the NCRI Cancer in Ireland 1994–2022 report (published October 2024)^[14].

What's on this page

Standard of care: The Dunne principles, set by the Supreme Court in Dunne v NMH, govern every Irish clinical negligence case^[1]. Dunne v National Maternity Hospital

Time limit: Two years less one day from your date of knowledge, under sections 2 and 3 of the Statute of Limitations (Amendment) Act 1991^[4]. Statute of Limitations (Amendment) Act 1991

No IRB stage: Medical negligence claims are exempt under section 3(d) of the PIAB Act 2003 and proceed directly to the High Court^[5]. PIAB Act 2003 s.3(d)

Court venue: The Clinical Negligence List, established by Practice Direction HC131 with effect from 28 April 2025^[9][10]. Practice Direction HC131 (Courts Service of Ireland)

What counts as ovarian cancer misdiagnosis under Irish law?

Under Irish law, ovarian cancer misdiagnosis is clinical negligence where a treating doctor's investigation, referral, or diagnostic decision fell below the standard set by the Dunne principles, and that failure caused you harm. The Supreme Court held in Dunne v National Maternity Hospital [1989] IR 91 that a doctor is negligent if no medical practitioner of equal status, acting with ordinary care, would have made the same decision in the same circumstances. According to Dunne v NMH (BAILII, 1989)^[1], the test recognises that medicine is an inexact science, but it doesn't protect a defective practice that's obviously unsafe.

The operative principle from Finlay CJ's judgment runs along these lines: a defendant practice supported by a responsible body of medical opinion is not negligent unless it has an inherent defect that ought to have been obvious to a person giving it due consideration. That sentence is the pivot for every Irish clinical negligence trial, including ovarian cancer claims.

The Dunne test is the Irish standard. It isn't the English Bolam or Bolitho test. Unlike in England and Wales, where the courts apply Bolam with the Bolitho gloss, Ireland applies Dunne, which requires the defendant practice to be supported by a responsible body of medical opinion and to be free of an obvious defect that no reasonable practitioner would tolerate.

Three things have to be proved on the balance of probabilities. First, breach of duty: the GP, radiologist, pathologist, or gynaecologist did something a competent peer wouldn't have done, or failed to do something a competent peer would have done. Second, causation: had the breach not happened, the outcome would have been better. Third, recoverable harm: a worse stage at diagnosis, more invasive surgery, infertility, shorter life expectancy, or death attributable to the delay.

From handling cancer misdiagnosis cases in Ireland, the most contested element is usually causation rather than breach. The defence will often accept that referral could have happened sooner but argue that the cancer was already established or that the prognosis was unaffected. Stage-shift evidence and treatment-impact evidence carry the case. We work through that further in the causation in delayed diagnosis guide.

The patterns most often seen in ovarian cancer cases cluster around three failure points. The first is repeated GP attendance for bloating, abdominal pain, or changed bowel habit being attributed to IBS, stress, or perimenopause without CA-125 ever being ordered. The second is a normal CA-125 closing the investigation prematurely while symptoms persist. The third is a known family history of breast or ovarian cancer that was either undocumented or never acted upon. Whether any of those patterns supports a claim depends entirely on the specific records and clinical chronology of the individual case.

The Irish Ovarian Diagnostic Gate: where breach happens

The NCCP GP Ovarian Cancer Referral Guideline, issued under the National Cancer Control Programme of the HSE, sets out the diagnostic pathway Irish GPs are expected to follow. These six decision points form the Irish Ovarian Diagnostic Gate: each gate has to open before the next one becomes relevant. According to the NCCP GP Referral Guidelines (HSE)^[12], persistent, frequent, or new symptoms in women over 50 trigger a defined investigative response.

Gate 1 is the symptom presentation. The NCCP cluster includes persistent abdominal distension or bloating, early satiety or appetite loss, pelvic or abdominal pain, and increased urinary urgency or frequency. The NCCP referral guideline directs Irish GPs to investigate when symptoms occur frequently, defined as more than 12 times a month, particularly in women aged 50 or over. New IBS-type symptoms in a woman over 50 in the previous 12 months are themselves a referral trigger because new IBS is rare in that age group. Gate 2 is history-taking: a complete family history covering breast and ovarian cancer in first-degree relatives, prior cancers, and current symptom duration.

Gate 3 is the CA-125 blood test. The accepted threshold is 35 IU/ml. Gate 4 is pelvic ultrasound, ordered when CA-125 is raised or when clinical suspicion remains despite a normal result. Gate 5 is specialist referral on a suspected-cancer pathway to a designated gynae-oncology centre. Gate 6 is the multidisciplinary team review, RMI calculation, and CT staging.

The Irish Ovarian Diagnostic Gate: what each gate is and where breach commonly occurs

Gate	What should happen	Common breach pattern
1. Symptom presentation	GP records persistent symptoms, frequency, and duration	Symptoms attributed to stress, IBS, menopause, or UTI without record review
2. History taking	Family cancer history and personal cancer history are taken	BRCA-relevant family history not asked about or not documented
3. CA-125	Blood test ordered when symptoms meet NCCP triggers	Test never ordered, or normal result treated as definitive
4. Pelvic ultrasound	Imaging arranged when CA-125 raised or clinical suspicion remains	Imaging not arranged, or complex cyst dismissed without follow-up
5. Specialist referral	Suspected-cancer referral to a designated gynae-oncology centre	Referral delayed, routed to general gynaecology, or downgraded to routine
6. MDT and staging	RMI calculated, CT staging, oncology MDT review	Staging incomplete, MDT not convened, treatment plan delayed

The four NCCP-designated gynae-oncology centres in the Republic are St James's Hospital Dublin, the Mater Misericordiae and St Vincent's joint service (which is jointly accredited by the European Society of Gynaecological Oncology for advanced ovarian cancer surgery), Cork University Maternity Hospital (within the CUH/UCC Cancer Centre), and University Hospital Galway. A referral routed away from those centres for advanced disease is itself a structural concern.

When does ovarian cancer get confused with IBS, a cyst, menopause, or a UTI?

Ovarian cancer is misdiagnosed across Irish primary care for a measurable reason. According to the Breakthrough Cancer Research awareness data (March 2024), 79% of Irish women weren't confident they could recognise the symptoms^[20], and the symptom set overlaps with several common, benign conditions seen daily by GPs.

The most common misattributions are irritable bowel syndrome, ovarian cysts categorised as benign, perimenopause or menopause, and recurrent urinary tract infections. The NCCP guideline addresses this directly: a woman over 50 presenting with new IBS-type symptoms in the last twelve months requires investigation, not reassurance. New IBS in this age group is itself a referral trigger.

The CA-125 test itself has well-documented limitations. Around 10 to 20% of ovarian cancers produce a normal CA-125 value, including a high proportion of mucinous, clear cell, and some early-stage epithelial tumours. A normal result doesn't exclude cancer when symptoms persist. Conversely, CA-125 can rise in endometriosis, fibroids, pelvic inflammatory disease, and pregnancy, generating false positives. The negligence in many cases isn't ordering CA-125 too late but treating a normal CA-125 as the end of the investigation when symptoms continue.

The same point applies to pelvic ultrasound. A complex cyst with septations thicker than 3 millimetres, solid components, or abnormal vascularity shouldn't be classified as straightforwardly benign without follow-up imaging or specialist review. Where the NCEC National Clinical Guideline No. 20 (2019)^[13] calls for an RMI calculation, that calculation should appear in the record.

The Ovarian Histology Breach Matrix

Ovarian cancer isn't a single disease, and the breach pattern in an Irish negligence case often tracks the histological subtype. According to the NCEC National Clinical Guideline No. 20 (2019), the four subtypes most relevant to misdiagnosis claims are high-grade serous carcinoma, granulosa cell tumours, germ cell tumours, and borderline tumours. Each subtype generates a distinct typical failure profile. The pattern is set out below as the Ovarian Histology Breach Matrix.

Ovarian Histology Breach Matrix: subtype, presentation, and typical failure point

Subtype	Typical presentation	Common failure point
High-grade serous carcinoma (HGSC)	Postmenopausal women, often fallopian-tube origin, late-stage at diagnosis	Symptom dismissal at primary care, with CA-125 not ordered or repeat testing not done
Granulosa cell tumour	Hormonal presentations, postmenopausal bleeding, pelvic mass	Postmenopausal bleeding worked up only as endometrial cause, with ovary not imaged
Germ cell tumours	Younger women under 40, rapid mass growth, pain	Symptoms attributed to pregnancy, ovarian cyst, or musculoskeletal cause, with no ultrasound arranged
Borderline ovarian tumour	Variable age, often asymptomatic, found on imaging	Pathology misclassification, with failure to refer for second opinion or staging

HGSC is the histology behind most of the late-stage cases in Ireland, and current understanding holds that many HGSCs originate in the fallopian-tube fimbria as serous tubal intraepithelial carcinoma, abbreviated to STIC. That biology matters legally because diagnostic responsibility extends to fallopian-tube assessment, not just the ovary itself, when imaging or surgical histology is reviewed. Where a salpingo-oophorectomy specimen is sent to pathology, the standard of care now includes a sectioning protocol called SEE-FIM (Sectioning and Extensively Examining the FIMbria), which deliberately searches for STIC lesions. A pathology report that documents only the ovaries without specifying that the fimbriae were sectioned and examined to that protocol can itself ground a breach argument where HGSC is later confirmed.

Granulosa cell tumours are an area where defendants sometimes argue the imaging looked benign. The counter-evidence comes from the hormonal picture: persistent postmenopausal bleeding, a raised inhibin or oestradiol, a pelvic mass on examination. A workup that addresses the bleeding only as an endometrial issue and doesn't image the ovaries can fall below the standard.

The timing matters more than most guides suggest. A six-month delay in HGSC can move a patient from Stage I, where five-year survival is around 90%, to Stage III, where it falls below 40%, according to long-running survival data tracked by the NCRI survival statistics by stage^[15]. That stage shift is the causation evidence.

When is failing to act on BRCA or Lynch family history negligent?

Around 15 to 20% of ovarian cancers in Ireland are linked to inherited mutations, most commonly in the BRCA1, BRCA2, and Lynch-syndrome genes. According to the National Centre for Medical Genetics referral guidance^[23], women with a strong family history of breast or ovarian cancer should be offered referral for genetic counselling and testing, and BRCA-positive women have access to risk-reducing salpingo-oophorectomy and intensive surveillance. The Irish BRCA1/2 mainstreaming pilot run across three tertiary centres and reported by McVeigh et al. in Familial Cancer in 2023 (epub August 2022) found a pathogenic variant yield of around 12% in the women tested^[21], which is consistent with international rates and supports the case for prompt genetic referral.

The negligence pattern is the missed family history conversation. A patient discloses, or has it in her records, that her mother died of ovarian cancer in her fifties and an aunt had breast cancer in her forties. She isn't referred for genetic testing. Years later she presents with advanced ovarian cancer, BRCA-positive on testing, and the question becomes whether earlier referral would have led to risk-reducing surgery or earlier detection.

This isn't theoretical. In July 2018 the High Court approved a €2 million settlement, without admission of liability, for a woman with terminal high-grade serous ovarian cancer who was later confirmed to carry a BRCA1 pathogenic mutation. The case was reported in the Irish media at the time. We don't present that figure as a benchmark for any other case. Each settlement turns on its own facts, and the Personal Injuries Guidelines 2021 frame the analysis.

Lynch syndrome, also called HNPCC, increases ovarian and endometrial cancer risk and runs in families with bowel cancer histories. Ovarian referral guidance covers Lynch testing where colorectal or endometrial cancer is in the family. A BRCA or Lynch failure pathway sits beside, and is sometimes the same case as, a breast cancer misdiagnosis claim, because the same family history triggers both.

How is causation evidence built in Irish ovarian cancer claims?

Causation in an Irish ovarian cancer misdiagnosis claim is built on stage-shift evidence: proof that earlier diagnosis would have caught the cancer at an earlier FIGO stage, with measurably better survival and treatment outcomes. According to the NCRI survival statistics, five-year net survival in Ireland varies dramatically by stage at diagnosis. The defence in late-stage cases will routinely argue the prognosis was unaffected by delay. The stage-shift table is how plaintiffs answer that argument.

Five-year net survival by FIGO stage at ovarian cancer diagnosis (Ireland and international data)

FIGO stage at diagnosis	Approximate 5-year net survival	Typical clinical picture
Stage I (confined to ovary)	Around 90%	Cancer detected before spread, with surgery often curative
Stage II (pelvic spread)	Around 70%	Spread within pelvis, with surgery plus chemotherapy
Stage III (abdominal spread)	Around 30 to 40%	Most common stage at diagnosis in Ireland, treated with debulking surgery and chemotherapy
Stage IV (distant metastases)	Below 20%	Spread beyond abdomen, with palliative-focused treatment plans

Around 70% of Irish ovarian cancer cases are diagnosed at Stage III or IV. NCRI net 5-year survival across all stages combined sits in the 46 to 50% range, which is below the EU average and reflects the late-stage skew in Irish diagnosis^[14][15]. A six-month delay can move a patient from Stage I to Stage III for fast-growing high-grade serous histology. That movement is the harm courts compensate, even where ultimate cure is not the alternative outcome. Irish jurisprudence has engaged with the lost-chance principle in Philp v Ryan [2004] IESC 105^[3], where the Supreme Court compensated a plaintiff with prostate cancer for the lost opportunity that an eight-month diagnostic delay had caused. The High Court awarded €45,000 in respect of that lost-chance distress, and the Supreme Court added a further €50,000 in aggravated damages because the defendants had falsified clinical notes, taking the total to €100,000. The Personal Injuries Guidelines 2021^[11] then frame the value of the resulting harm.

Why is the Irish ovarian pathway different from the UK pathway?

The Irish ovarian cancer diagnostic pathway is set by the NCCP under the HSE, not by NICE. Many search results for "ovarian cancer misdiagnosis claim" surface UK pages that describe NICE guideline CG122, the NHS two-week-wait pathway, and a three-year limitation period under the Limitation Act 1980. None of those rules apply in Ireland. The differences are not cosmetic. They change how breach is judged, where claims are issued, and how long claimants have to act.

Pathway and procedural differences between Ireland and England and Wales

Element	Ireland	England and Wales
Standard of care	Dunne v National Maternity Hospital [1989] IR 91	Bolam with the Bolitho gloss
Limitation period	Two years less one day from date of knowledge	Three years from date of knowledge
Pre-action body	None for medical negligence (IRB exempt under PIAB Act 2003 s.3(d))	Pre-action protocol under the Civil Procedure Rules
Issuing court	High Court, Clinical Negligence List under HC131	High Court Queen's Bench / Senior Courts
Diagnostic guideline	NCCP GP Ovarian Cancer Referral Guideline (HSE)	NICE CG122 and the suspected cancer pathway under NG12
Two-week wait pathway	No nationwide two-week ovarian pathway, with NCCP referral routing to NCCP-designated cancer centres	Two-week wait referral mandated for suspected cancer
Compensation framework	Personal Injuries Guidelines 2021 (Judicial Council)	Judicial College Guidelines (different ranges)
Indemnifier for State care	State Claims Agency under the Clinical Indemnity Scheme	NHS Resolution under the Clinical Negligence Scheme for Trusts

The most consequential differences for someone considering a claim are the standard of care test and the limitation period. A solicitor in England would build the medical evidence around what a responsible body of doctors would have done under Bolam. An Irish solicitor builds it around what no medical practitioner of equal status would have done under Dunne. The two tests can produce different outcomes on the same facts, which is one reason cross-border cases benefit from Irish-specific advice early.

What is the time limit for an ovarian cancer claim in Ireland?

The time limit in Ireland is two years less one day from your date of knowledge under sections 2 and 3 of the Statute of Limitations (Amendment) Act 1991^[4]: section 2 defines the date of knowledge, and section 3 fixes the two-year period running from it. According to Citizens Information on civil time limits (2025)^[17], the clock doesn't necessarily start when the negligent act happened. It starts when you knew, or ought reasonably to have known, that you had been significantly injured and that the injury was attributable to the act or omission complained of.

Unlike in England and Wales, where the limitation period is generally three years and personal-injury claims have a different procedural framework, Ireland's two-year rule is shorter and unforgiving. The "less one day" is the result of the way limitation is calculated under Irish practice, and proceedings need to be issued before that date.

For ovarian cancer specifically, the date of knowledge can be later than people assume. A woman diagnosed at Stage IV may not realise the relevance of her three earlier GP visits until a treating consultant tells her the cancer should have been investigated sooner. The clock typically starts at that conversation, not at the original visits. The detail matters and is set out further on the date of knowledge page.

Two further points. First, section 71 of the Statute of Limitations 1957 can extend time where there has been fraud or deliberate concealment. Second, for a person who lacked mental capacity, the clock may not start until capacity returns. For minors, the clock starts at age 18. Each of these is a narrow exception. Most ovarian cancer claims live or die on the standard date-of-knowledge analysis described above and at two-year limitation rule.

How much compensation can you claim for ovarian cancer misdiagnosis in Ireland?

Compensation in an Irish ovarian cancer misdiagnosis claim is calculated using the Personal Injuries Guidelines 2021 (Judicial Council)^[11], which replaced the Book of Quantum from 24 April 2021. According to the Judicial Council, the Guidelines bind the courts and the Injuries Resolution Board. Where bodily injury sits at the centre, the relevant chapters cover loss of reproductive organs, scarring, infertility with psychological sequelae, reduced life expectancy, and pain and suffering. A 16.7% uplift was proposed in early 2025 but the Government decided in July 2025 not to advance the amendments to the Oireachtas, so the original 2021 brackets remain applicable in 2026.

Compensation has two parts. General damages address pain, suffering, and loss of amenity. Special damages cover proven financial losses, including past and future medical costs, loss of earnings, future care needs, home adaptations, and out-of-pocket expenses. We aren't allowed to publish guarantees or averages. Awards depend on the specific facts of each case.

Heads of damage typically considered in ovarian cancer claims, with ranges depending on facts and prognosis

Head of damage	What it covers	Where it's set out
General damages	Pain and suffering, surgery and chemotherapy impact, loss of amenity, psychological injury	Personal Injuries Guidelines 2021, relevant chapter
Loss of reproductive function	Hysterectomy, bilateral salpingo-oophorectomy, infertility, hormonal sequelae	Guidelines 2021, reproductive system chapter
Reduced life expectancy	Where stage shift means prognosis is worse than it would have been	General principles plus medical evidence
Loss of earnings	Past and future earnings lost to treatment, recovery, or shortened working life	Vouched financial evidence
Future care and rehabilitation	Care assistance, palliative care, rehabilitation, equipment	Care expert report and life-cost projection
Medical expenses and travel	Hospital costs, private treatment, travel to specialist centres	Vouched receipts and itinerary

For deeper detail on each head, see the cluster pages on general damages, special damages, future care costs, and medical expenses and travel. Where bereavement is involved, the solatium cap under section 49 of the Civil Liability Act 1961^[6] (as raised to €35,000 by S.I. No. 6 of 2014, with effect from 11 January 2014^[22]) is €35,000 in total, shared among all statutory dependants. It isn't €35,000 per dependant.

The Circuit Court has personal-injuries jurisdiction up to €60,000. Cases above that figure proceed in the High Court on the Clinical Negligence List. Most ovarian cancer cases of any substance run in the High Court because of stage-shift, future care, and dependency claims that take general and special damages above the Circuit threshold.

Who pays an ovarian cancer misdiagnosis claim in Ireland?

Liability in an Irish ovarian cancer misdiagnosis claim is allocated by reference to who provided the care that fell below standard. According to the NTMA Annual Report 2024 (published July 2025), the State Claims Agency defended HSE and Tusla clinical claims and paid out approximately €210.5 million in damages across all clinical claim categories in 2024^[18]. The defendant identity matters because it determines who handles the case, who provides indemnity, and how complex the procedural picture becomes.

Three patterns predominate. If the care happened in an HSE hospital, a HSE-funded service, or with a HSE-employed clinician, the State Claims Agency manages the defence and the State indemnifies under the Clinical Indemnity Scheme. If a consultant in independent practice was responsible, that consultant's medical defence body, typically the Medical Protection Society or Medisec, indemnifies and instructs solicitors. If the negligence happened in a private hospital, that hospital's insurer engages, alongside any consultant indemnifier.

The Morrissey v HSE [2020] IESC 6 judgment of the Supreme Court confirmed that the HSE owes a non-delegable duty of care for services it operates, even where outsourced laboratories or contractors do part of the work^[2]. According to Morrissey v HSE [2020] IESC 6 (BAILII), that ruling shapes how cancer-screening and cancer-diagnosis liability flows back to the HSE. Although Morrissey was a CervicalCheck case, the non-delegable-duty reasoning is regularly cited in cancer diagnostic delay litigation generally. The implications for HSE liability are set out at claims against the HSE.

How does the claim process actually work in Ireland?

The Irish ovarian cancer misdiagnosis process runs in five stages, anchored to the Clinical Negligence List under Practice Direction HC131^[9]. The Practice Direction took effect on 28 April 2025 and requires parties seeking a trial date to give an undertaking to offer mediation, which has reshaped the timeline since spring 2025.

The five stages are consultation, evidence gathering, proceedings, negotiation or mediation, and resolution. Most cases settle before trial. Mediation rates in clinical negligence under the State Claims Agency framework ran at 43% in 2024, and only around 2% of clinical claims reached a court judgment that year^[18].

Stage 1 is the consultation. A solicitor takes a chronological account, identifies the relevant care providers, and estimates the date of knowledge. Stage 2 is records and expert. Medical records are requested under data protection access rights, and an independent expert report is commissioned, usually from a UK or Irish gynaecological oncologist who will assess breach and causation. The records and expert work is set out at medical records request process and independent expert medical report.

Stage 3 issues High Court proceedings. A Personal Injury Summons is filed in the Central Office, and the Clinical Negligence List under HC131 and HC132 takes case management. Stage 4 covers negotiation and HC131 mediation. Mediation isn't mandatory, but the undertaking to offer it is, and unreasonable refusal can affect costs under the Mediation Act 2017. Stage 5 is resolution, by settlement (most cases) or trial.

Realistic timelines depend on liability disputes and the medical complexity of causation. Straightforward cases with admitted liability resolve in 18 to 30 months. Disputed liability and complex causation cases can run three to five years. The detailed pacing is on typical claim timeline.

Where proceedings are likely, an early letter under section 8 of the Civil Liability and Courts Act 2004 is the formal first move^[7]. The section 8 letter notifies the proposed defendant of the alleged wrongdoing and the loss it caused. Since 28 January 2019, when section 13 of the Central Bank (National Claims Information Database) Act 2018 amended the rule, the letter must be served within one month of the date of the cause of action. Where the letter is served late without reasonable cause, the court must draw such adverse inferences as it considers proper and may, where the interests of justice require, deduct from any costs payable to the plaintiff. In ovarian cancer cases, the letter goes to the HSE, the relevant hospital, the consultant indemnifier, or the private hospital insurer, depending on where the breach occurred.

How to start an ovarian cancer misdiagnosis claim in Ireland

If you are considering a claim, the practical sequence has five steps. Each step takes weeks to months. The earlier you begin, the more breathing room there is on the limitation clock.

1. Document your chronology. Write down every relevant GP visit, hospital appointment, scan, and conversation, with dates as best you can remember.
2. Request your medical records. Submit a written subject access request to your GP and to every hospital that treated you. Records typically arrive within one month.
3. Speak with a clinical-negligence solicitor. Bring the chronology and any records you already have. The first conversation scopes whether the case is viable and identifies the date of knowledge.
4. Consent to an independent expert review. The solicitor instructs an independent gynaecological oncologist to review the records and report on breach and causation.
5. Issue proceedings if the expert report supports the claim. The Personal Injury Summons is filed in the High Court Central Office and the Clinical Negligence List takes case management.

What if your case is more complex than the standard pathway?

The sections above cover the core legal framework, the diagnostic pathway, and the standard claim process. Some cases sit outside that standard frame. Bereaved relatives, claims involving the diagnostic infrastructure as a whole rather than one clinician, and cases where the defence runs hard on causation each shift the analysis. The next three sections deal with those scenarios in turn.

Can you claim after a loved one has died from ovarian cancer?

If a relative has died from ovarian cancer in circumstances suggesting misdiagnosis, Irish law allows two distinct claims: an estate claim under the Civil Liability Act 1961 and a dependency claim by statutory dependants. According to the Civil Liability Act 1961 (as amended)^[6], the estate inherits the deceased's right to sue for the period before death, and statutory dependants can recover for financial dependency lost as a result.

The estate claim covers what the deceased could have recovered up to her death, including pain and suffering and special damages. Dependency damages address the financial loss to a spouse or children. A solatium award for mental distress is available, capped at €35,000 in total to be shared among all statutory dependants, not paid per dependant. We work through the structure on claim after death and estate claims.

The two-year clock runs from the date of death or the date of knowledge of the negligence, whichever is later. For families, the practical question is usually when did they understand that the cancer had been investigated inadequately, which is often only after the post-mortem and records review. Bereaved relatives shouldn't assume time has run.

Ireland in context: diagnostic infrastructure matters

Ireland's diagnostic infrastructure forms the backdrop to most ovarian cancer misdiagnosis cases. According to the EU Country Cancer Profile: Ireland 2025 (OECD and European Commission)^[19], Ireland has the second-highest age-standardised cancer incidence in the EU, the third-highest cancer mortality in Western Europe, and notable shortages in MRI and CT capacity per capita relative to the EU average. The system context doesn't excuse breach, but it shapes the realistic timescales for investigation.

The other relevant fact is the absence of an ovarian-specific screening programme. there's no Irish equivalent to BreastCheck, CervicalCheck, or BowelScreen for ovarian cancer, because population screening with CA-125 and ultrasound didn't reduce mortality in the UK Collaborative Trial of Ovarian Cancer Screening (the UKCTOCS Lancet 2021 long-term follow-up). The clinical implication is that early detection in Ireland depends on symptomatic presentation being investigated correctly. The legal implication is that diagnostic duty rests heavily on the GP at first symptom presentation.

Patient Safety Act 2023 commencement is relevant but limited. According to the Department of Health commencement notice (September 2024)^[16], the Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023^[8] was commenced on 26 September 2024, introducing mandatory open disclosure of notifiable incidents and the cancer screening review right. The only provision not yet commenced is section 68 of the Act, which inserts a new section into the Health Act 2007 covering HIQA reviews of certain nursing home incidents. The cancer screening review right applies to BreastCheck, CervicalCheck, and BowelScreen. Because there's no Irish ovarian screening programme, that specific review right doesn't directly apply to ovarian cancer, although the broader mandatory open-disclosure framework does.

What are the common defences in ovarian cancer misdiagnosis claims?

According to the State Claims Agency's annual reporting and observable Irish High Court patterns, defendants in ovarian cancer claims typically run three lines of defence. Identifying which line is most likely is part of the early case build, because the evidence required differs in each.

The first defence is "no breach": the GP or specialist acted as competent peers would have, the symptoms were genuinely consistent with a benign cause, and Dunne isn't satisfied. The counter-evidence is the NCCP guideline, the symptom record, and the practice of competent peers as set out by an independent expert.

The second defence is "no causation": even with earlier referral, the cancer biology meant the outcome would have been the same. This is the central battleground in late-stage cases. Stage-shift evidence, treatment-impact evidence, and survival-curve analysis matter. Irish courts have engaged with the lost-chance concept, including in Philp v Ryan [2004] IESC 105^[3], where the High Court awarded €45,000 for the lost-chance distress and the Supreme Court added a further €50,000 in aggravated damages for the defendants' falsification of clinical notes. Lost-chance reasoning supplements rather than replaces standard balance-of-probabilities causation, and it's fact-specific.

The third defence is "consent and contributory factors": the patient delayed presenting, missed appointments, or failed to escalate symptoms. This rarely succeeds where records show repeated GP attendance and where the NCCP referral pathway wasn't followed. Causes outside the defendant's control, by contrast, aren't a complete defence. They go to apportionment under the Civil Liability Act 1961. The wider framework is covered at common defences in medical negligence claims and breach of duty in medical negligence.

What mistakes weaken or end an ovarian cancer misdiagnosis claim?

Some claims fail not because the medicine was wrong but because the legal procedure was. Across Irish High Court patterns, the same mistakes recur. Avoiding them costs nothing.

• Waiting until treatment finishes. Treatment doesn't pause the limitation clock. The two-year clock runs from your date of knowledge regardless of where you are in chemotherapy or surgery.
• Assuming the date of knowledge is the date of diagnosis. The date of knowledge is when you reasonably understood the cancer should have been investigated sooner, which is often weeks or months after diagnosis when a treating consultant explains it.
• Filing through the IRB. Medical negligence is exempt under section 3(d) of the PIAB Act 2003. Time spent on an IRB application is wasted and can erode the limitation period.
• Signing a complaint resolution agreement without legal review. Some HSE complaint resolutions include settlement language that may affect a future claim. Do not sign without independent legal advice.
• Discarding records as you receive them. Keep every appointment letter, scan report, and discharge summary. The case is only as strong as the records.
• Going public on social media. Posting clinical details, doctor names, or hospital criticisms publicly can complicate the claim and the underlying disclosure framework under the Patient Safety Act 2023.
• Engaging a solicitor without clinical-negligence experience. Ovarian cancer cases need a solicitor who routinely instructs gynae-oncology experts and runs cases on the Clinical Negligence List. The change solicitor mid-claim page covers what to do if your current solicitor is not the right fit.

Plain-English glossary of ovarian cancer claim terms

The medical and legal vocabulary in an ovarian cancer claim can be dense. The definitions below are the working terms most often encountered in Irish cases.

Glossary of clinical and legal terms used in ovarian cancer misdiagnosis claims in Ireland

Term	What it means in this context
CA-125	A protein in the blood that can be raised in ovarian cancer. The NCCP-recognised threshold is 35 IU/ml. Around 10 to 20% of ovarian cancers produce a normal CA-125, so the test cannot rule out cancer on its own.
Pelvic ultrasound	An imaging test that visualises the ovaries, fallopian tubes, and uterus. Where CA-125 is raised or clinical suspicion remains, ultrasound is the next step under the NCCP pathway.
RMI	Risk of Malignancy Index. A score combining CA-125, ultrasound features, and menopausal status to estimate the probability that a pelvic mass is cancerous. Set out in NCEC NCG No. 20.
HGSC	High-grade serous carcinoma. The most common ovarian cancer histology in Ireland. Often originates in the fallopian tube as STIC.
STIC	Serous tubal intraepithelial carcinoma. A precursor lesion in the fallopian tube fimbria from which most HGSCs are now thought to arise.
SEE-FIM	Sectioning and Extensively Examining the FIMbria. The pathology protocol for systematically searching the fallopian tube for STIC lesions.
FIGO staging	The international staging system for ovarian cancer (Stage I to IV). Determines treatment options and prognosis.
BRCA1 and BRCA2	Genes that, when mutated, substantially raise lifetime breast and ovarian cancer risk. Carriers can access risk-reducing surgery and intensive surveillance.
Lynch syndrome	An inherited condition (also called HNPCC) raising ovarian, endometrial, and bowel cancer risk. Triggers genetic testing where the family history fits.
NCCP	National Cancer Control Programme. The HSE body that issues Irish cancer guidelines, including the GP Ovarian Cancer Referral Guideline.
NCEC	National Clinical Effectiveness Committee. Issues NCEC National Clinical Guidelines, including NCG No. 20 on ovarian cancer diagnosis and staging.
NCCP-designated centres	The four gynae-oncology centres designated by the National Cancer Control Programme (HSE) in the Republic: St James's Hospital Dublin, the Mater Misericordiae and St Vincent's joint service in Dublin (also ESGO-accredited for advanced ovarian cancer surgery), Cork University Maternity Hospital (within the CUH/UCC Cancer Centre), and University Hospital Galway.
Dunne principles	The Irish standard of care, set in Dunne v National Maternity Hospital [1989] IR 91. A doctor is negligent if no medical practitioner of equal status acting with ordinary care would have made the same decision.
Date of knowledge	The date the claimant knew or ought reasonably to have known of significant injury attributable to a wrongful act. Defined in section 2 of the Statute of Limitations (Amendment) Act 1991. The two-year clock under section 3 of the same Act runs from this date.
IRB	Injuries Resolution Board, formerly the Personal Injuries Assessment Board (PIAB). Medical negligence claims are exempt under section 3(d) of the PIAB Act 2003.
Solatium	The statutory bereavement award for mental distress to statutory dependants under section 49 of the Civil Liability Act 1961. Capped at €35,000 in total (raised from €25,394.76 by S.I. No. 6 of 2014, applicable where the wrongful death occurs on or after 11 January 2014), shared among all dependants.
Section 8 letter	A pre-action letter required by section 8 of the Civil Liability and Courts Act 2004, notifying the defendant of the proposed claim.
HC131 and HC132	High Court Practice Directions effective 28 April 2025. HC131 requires a mediation undertaking, and HC132 created the Clinical Negligence List for case management.

Frequently asked questions about ovarian cancer misdiagnosis claims

What does ovarian cancer misdiagnosis mean in Irish law?

In Ireland, ovarian cancer misdiagnosis is clinical negligence where a GP, radiologist, pathologist, or gynaecologist failed to investigate, refer, or diagnose to the standard set in Dunne v National Maternity Hospital [1989] IR 91, and that failure caused harm. Generic diagnostic difficulty doesn't excuse breach.

• Breach is judged against competent peers in the same specialty.
• The NCCP referral guideline frames the expected investigative steps.
• Causation requires evidence that earlier diagnosis would have changed the outcome.

How long do I have to bring an ovarian cancer claim in Ireland?

You have two years less one day from your date of knowledge under sections 2 and 3 of the Statute of Limitations (Amendment) Act 1991. The clock often starts when a treating consultant tells you the cancer should have been investigated sooner, not at the original missed visits.

• Date of knowledge can be later than the negligent act.
• Section 71 fraud or concealment can extend time in narrow cases.
• For a deceased person, time runs from death or knowledge, whichever is later.

Do I have to go through the IRB, formerly PIAB, for an ovarian cancer claim?

No. Medical negligence claims are exempt from the Injuries Resolution Board, formerly the Personal Injuries Assessment Board, under section 3(d) of the PIAB Act 2003. Ovarian cancer misdiagnosis claims proceed directly to the High Court on the Clinical Negligence List.

• The IRB exemption applies to all clinical negligence.
• The Central Office issues a Personal Injury Summons.
• The Clinical Negligence List manages the case under HC131 and HC132.

Can a normal CA-125 result still mean I had cancer?

Yes. About 10 to 20% of ovarian cancers, especially mucinous tumours and some early-stage epithelial cancers, produce a normal CA-125 value. A normal result doesn't exclude cancer when symptoms persist. The Irish negligence question is whether investigation continued.

• CA-125 has documented false-negative rates.
• The NCCP guideline calls for ultrasound when clinical suspicion remains.
• A normal CA-125 used as the end of the workup is a common breach pattern.

I have a BRCA family history and was never offered testing. Is that negligence?

It can be. National Centre for Medical Genetics guidance recommends referral for genetic counselling and testing where there's a strong family history of breast or ovarian cancer. Failure to take or act on a documented family history is a breach pattern courts and experts recognise.

• The records have to show what family history was known.
• Causation depends on whether earlier testing would have changed events.
• Risk-reducing surgery for BRCA-positive women is a recognised pathway.

How long does an ovarian cancer misdiagnosis claim take in Ireland?

From instruction to resolution, straightforward cases with admitted liability typically run 18 to 30 months in Ireland. Disputed liability and complex causation cases can run three to five years. HC131 mediation has shortened average timelines in clinical negligence since April 2025.

• Records and expert reports take six to nine months on average.
• Most cases settle before trial.
• HC131 requires a mediation undertaking when seeking a trial date.

Can I claim if I was treated in a private hospital like the Mater Private or Beacon?

Yes. Private hospital treatment in Ireland is covered by the same Dunne standard as HSE care. The defendant differs: a private hospital and its consultants engage their own indemnifiers, which is typically a medical defence body for the consultant and a hospital insurer for the institution.

• The clinical standard doesn't change between public and private.
• The procedural defendant identity changes.
• The Clinical Negligence List handles both.

Will making a claim affect my ongoing medical care?

No. Withdrawing care from a patient because she has made a complaint or claim is itself a breach of professional duty in Ireland. Patients are entitled to continue receiving treatment from the HSE or any provider during a claim, and confidential records are protected.

• Treatment continues unaffected by the claim.
• You can request a transfer of care if confidence has broken down.
• Confidentiality is preserved by data protection law.

Do I pay anything up front under no win no fee?

In contentious business, a solicitor may not calculate fees as a percentage or proportion of any award or settlement, under the Solicitors Act and the LSRA Statutory Instrument 644 of 2020. Most Irish clinical negligence work runs on a deferred-fee basis subject to a Section 150 notice.

• You receive a written Section 150 notice at the outset.
• Outlay funding for records and experts is a separate question.
• After-the-event insurance can cover adverse costs in some cases.

What evidence do I need to start an ovarian cancer claim?

You need a clear chronology, your full medical records (GP, hospital, imaging, pathology), and an independent expert report on breach and causation. A solicitor commissions the expert report after the records are in. Family information about cancer history can also be decisive in BRCA-related claims.

• GP notes covering the period before diagnosis are essential.
• Imaging and pathology reports often resolve specific breach questions.
• Family cancer history strengthens BRCA and Lynch failure cases.

Can a GP be sued for missing ovarian cancer in Ireland?

Yes. A GP is liable in Irish law where investigation, referral, or follow-up fell below the standard a competent peer would have met under Dunne v National Maternity Hospital [1989] IR 91, and where that failure caused measurable harm. The NCCP GP Ovarian Cancer Referral Guideline frames the expected steps for persistent or new symptoms in women over 50.

• The GP's medical defence body, often Medical Protection Society or Medisec, indemnifies the practice.
• Independent expert evidence from a peer GP or oncologist is required to prove breach.
• Causation is built on stage shift between actual and counterfactual diagnosis dates.

What is the date of knowledge for an ovarian cancer claim?

The date of knowledge is the day you knew, or ought reasonably to have known, that you had been significantly injured and that the injury was attributable to the act or omission complained of. Section 2 of the Statute of Limitations (Amendment) Act 1991 defines it. For ovarian cancer, the date often falls when a treating consultant tells the patient that earlier investigation was warranted.

• The date of knowledge can be later than the negligent act itself.
• Medical opinion that earlier investigation was indicated typically triggers the clock.
• The two-year-less-one-day clock then runs from that date.

How does mediation work under HC131?

Practice Direction HC131, effective 28 April 2025, requires parties seeking a trial date in the High Court Clinical Negligence List to give an undertaking to offer mediation. Mediation isn't compulsory, but the offer is. Failure to mediate without good reason can affect costs under the Mediation Act 2017. State Claims Agency data show 43% of concluded clinical claims in 2024 involved mediation.

• The mediation undertaking is filed before the trial date is fixed.
• An accredited mediator agreed between the parties facilitates the session.
• Settlements reached at mediation are recorded in writing and binding once signed.

What is the Risk of Malignancy Index (RMI) in ovarian cancer?

The Risk of Malignancy Index is a calculation that combines a CA-125 value, an ultrasound score, and menopausal status to estimate the probability that an ovarian mass is malignant. NCEC National Clinical Guideline No. 20 (2019) calls for an RMI calculation in suspected ovarian cancer. Where the RMI score isn't documented, it raises a documented breach pattern in the records.

• RMI scores above 200 generally indicate referral to a designated centre.
• The calculation should appear in the consultant or GP record.
• Missing RMI is one of the most common breach indicators in pelvic-mass cases.

Who is the defendant in an ovarian cancer claim: doctor, hospital, or HSE?

The defendant depends on where the care happened. HSE-employed clinicians and HSE hospitals are defended by the State Claims Agency under the Clinical Indemnity Scheme. A consultant in independent practice is defended by their medical defence body, typically Medical Protection Society or Medisec. A private hospital is defended by its insurer. Most ovarian cancer cases involve more than one defendant because care typically crossed primary, secondary, and tertiary settings.

• Identifying every potential defendant is part of the early case build.
• The HSE owes a non-delegable duty for services it operates, per Morrissey v HSE [2020] IESC 6.
• Joint defendants are sued together where breach was shared across providers.

What to consider next

If the questions above prompt others, the most common follow-ups touch on three areas: how the cluster of family-history cancers is handled together, how the timeline interacts with treatment decisions, and what bereaved relatives should do in the early weeks after a death.

Should I bring a separate breast cancer claim if BRCA testing was missed? Often the same family-history failure is at the heart of both. Coordinated handling of any overlap with a breast cancer misdiagnosis claim means the records and expert evidence carry across rather than duplicate.

How does treatment affect the limitation clock? Treatment doesn't stop or restart the limitation clock. The clock runs from your date of knowledge, which can fall before, during, or after a treatment course. Where doubt exists, the safest course is to seek advice now rather than wait for treatment to finish.

What should bereaved families do in the first six months? Request the medical records, secure copies of any inquest documentation, and identify the statutory dependants. The claim after death and estate claims page sets out the order of steps.

References

Sources are numbered for inline citation. Statutes and Supreme Court case law are primary. Clinical guidelines, official statistics, and government commencement notices are secondary. Advocacy and EU comparative data complete the picture.

1. Dunne v National Maternity Hospital [1989] IR 91. Supreme Court of Ireland, judgment 14 April 1989 (Finlay CJ). BAILII.
2. Morrissey & anor v Health Service Executive & ors [2020] IESC 6. Supreme Court of Ireland, judgment 19 March 2020 (Clarke CJ). BAILII.
3. Philp v Ryan & Anor [2004] IESC 105. Supreme Court of Ireland, judgment 16 December 2004 (Fennelly J; McCracken J concurring on aggravated damages). vLex Ireland.
4. Statute of Limitations (Amendment) Act 1991, sections 2 and 3. Revised Acts, Law Reform Commission. revisedacts.lawreform.ie.
5. Personal Injuries Assessment Board Act 2003, section 3(d). Irish Statute Book. irishstatutebook.ie.
6. Civil Liability Act 1961 (as amended). Revised Acts, Law Reform Commission. Includes section 49 (solatium for mental distress, capped at €35,000 by S.I. No. 6 of 2014, effective 11 January 2014). revisedacts.lawreform.ie.
7. Civil Liability and Courts Act 2004, section 8 (Revised). One-month letter-of-claim rule as amended by section 13 of the Central Bank (National Claims Information Database) Act 2018, effective 28 January 2019. revisedacts.lawreform.ie.
8. Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023. Irish Statute Book. irishstatutebook.ie.
9. High Court Practice Direction HC131: Clinical Negligence Actions — Applications for Trial Dates. Effective 28 April 2025. Courts Service of Ireland. courts.ie.
10. High Court Practice Direction HC132: Clinical Negligence List. Effective 28 April 2025. Courts Service of Ireland. courts.ie.
11. Personal Injuries Guidelines 2021 (1st edition). Judicial Council of Ireland; in effect from 24 April 2021. The proposed 16.7% uplift submitted to the Minister for Justice in February 2025 was not advanced to the Oireachtas in July 2025. judicialcouncil.ie.
12. NCCP GP Ovarian Cancer Referral Guideline. HSE National Cancer Control Programme. hse.ie.
13. NCEC National Clinical Guideline No. 20: Diagnosis and Staging of Patients with Ovarian Cancer (2019). National Clinical Effectiveness Committee, Department of Health. gov.ie.
14. National Cancer Registry Ireland (2024). Cancer in Ireland 1994–2022: Annual statistical report of the National Cancer Registry. Cork: NCRI, October 2024. ncri.ie.
15. NCRI Survival Statistics by Stage at Diagnosis. National Cancer Registry Ireland interactive tool. ncri.ie.
16. Department of Health (26 September 2024). Minister for Health announces commencement of the Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023. Section 68 (Health Act 2007 amendment for HIQA review of nursing-home incidents) remains uncommenced as of April 2026. gov.ie.
17. Citizens Information. Time limits for bringing civil cases (updated 2025). citizensinformation.ie.
18. State Claims Agency. NTMA Annual Report 2024 (published July 2025). Clinical claims damages paid in 2024: €210.5 million; 43% of concluded clinical claims involved mediation; about 2% reached court judgment; estimated outstanding liability €5.35 billion. stateclaims.ie.
19. OECD and European Commission (2025). EU Country Cancer Profile: Ireland 2025. health.ec.europa.eu.
20. Breakthrough Cancer Research / Irish Network for Gynaecological Oncology. Awareness research (Behaviour & Attitudes survey): 79% of Irish women not confident they could recognise symptoms of ovarian cancer. breakthroughcancerresearch.ie.
21. McVeigh TP et al. (2023). A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland. Familial Cancer 22(2):135–149 (epub 27 August 2022). Pathogenic variant yield 12% (12/101). Springer Nature Link.
22. Civil Liability Act 1961 (Section 49) Order 2014, S.I. No. 6 of 2014. Solatium increased to €35,000 with effect from 11 January 2014. Law Society of Ireland: Application of new solatium limit.
23. National Centre for Medical Genetics (Children's Health Ireland at Crumlin). Referral guidance for hereditary cancer testing. nccgenetics.ie.